FDASIA Taxonomy Subgroup HIT Policy Committee FDASIA Workgroup On Site Meeting 30 May 2013.

Slides:



Advertisements
Similar presentations
Elizabeth Mansfield, PhD OIVD Public meeting July 19, 2010
Advertisements

Development Cycle of Medical Devices: A Path of Opportunities for Information Professionals Donna Gay Pharma & Health Tech Div, SLA 2007 Spring Meeting.
Legal Work Group Developing a Uniform EHR/HIE Patient Consent Form.
Sorenson Medical, West Jordan, Utah USA Medical Device Development Robert Hitchcock, Ph.D. Director of Engineering & Technology Development Sorenson Medical,
Regulatory Pathway for Platform Technologies
Medication Management
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
HIPAA: Privacy, Security, and HITECH, Oh My! Presented by Stephanie L. Ganucheau, Special Assistant Attorney General.
Information Risk Management Key Component for HIPAA Security Compliance Ann Geyer Tunitas Group
TM The HIPAA Privacy Rule: Safeguarding Health Information in Research and Public Health Practice Centers for Disease Control and Prevention Beverly A.
CHAPTER © 2011 The McGraw-Hill Companies, Inc. All rights reserved. 2 The Use of Health Information Technology in Physician Practices.
QA Programs for Local Health Departments
FDASIA Committee Background David W. Bates MD, MSc, Chair 1.
Assignment Four Underwriting. Definitions Underwriting – The process of selecting policyholders by recognizing and evaluation hazards, establishing prices.
Capturing and Reporting Adverse Events in Clinical Research
© Copyright 2014 Saul Ewing LLP The Coalition for Academic Scientific Computation HIPAA Legal Framework and Breach Analysis Presented by: Bruce D. Armon,
Introduction to Regulation
Medical Devices Approval Process
Office of the National Coordinator for Health IT (ONC) Certification Program June 19, 2013 Lauren Fifield, Policy Adviser, Practice Fusion.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Clinical Pharmacy Basma Y. Kentab MSc..
Weaving regulations into sound value analysis processes Barbara Strain, MA, SM(ASCP) Director Value Management University of Virginia Health System.
Is this Research? Exempt? Expedited?
Product Definition Chapter 4. What is a Medical Device? FDA: “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent,
The University of Kansas Medical Center Shadow Experience Training.
HIT Policy Committee Accountable Care Workgroup – Kickoff Meeting May 17, :00 – 2:00 PM Eastern.
Presented by: George Howe Executive Vice President Business Development & OEM Accounts.
FDASIA REGULATIONS SUBCOMMITTEE May 22, Agenda 4:00 p.m.Call to Order – MacKenzie Robertson Office of the National Coordinator for Health Information.
Decision Support for Quality Improvement
FDASIA Health IT Report Jodi G. Daniel, JD, MPH Director, Office of Policy and Planning, ONC May 6, 2014.
Device Research Presented by Marian Serge, R.N.. Goals Identify devices Recognize difference between significant risk (SR) and non- significant risk (NSR)
Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
1 Importation of Medical Devices FDA Chicago District O’Hare Import Resident Post August 26, 2010 Import Entry Review Team Tamara M. Qtami, CSO.
Software Quality Assurance Lecture 4. Lecture Outline ISO ISO 9000 Series of Standards ISO 9001: 2000 Overview ISO 9001: 2008 ISO 9003: 2004 Overview.
Medical Devices IRB Determination IRB Member Continuing Education.
Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.
© 2011 Underwriters Laboratories Inc. All rights reserved. This document may not be reproduced or distributed without authorization. ASSET Safety Management.
Risk Assessments: Patient Safety and Innovation Innovation Discussion 02 July 2013.
Applying Science to Transform Lives TREATMENT RESEARCH INSTITUTE TRI science addiction Mady Chalk, Ph.D Treatment Research Institute CADPAAC Conference.
M. Frize, Winter 2003 Reliability and Medical Devices Prof. Monique Frize, P. Eng., O.C. ELG5123/ February 2003.
FDA Public Meeting on Electronic Records and Signatures June 11, 2004 Presentation of the Industry Coalition on 21CFR Part 11 Alan Goldhammer, PhD Chair.
This class cannot be shared or copied without the written permission of PracticeWorks Systems, LLC.
Risk Assessments: Patient Safety and Innovation 20 May 2013.
FDASIA Taxonomy Subgroup HIT Policy Committee FDASIA Workgroup Virtual Meeting 14 June 2013.
Risk Assessments: Patient Safety and Innovation Paul Tang, MD Keith Larsen, RPh.
Medication Error Reduction Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
Investigational Devices and Humanitarian Use Devices June 2007.
REGULATION OF MEDICAL DEVICES INNOVATION TUĞÇE YAŞAR
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
Alex Ezrakhovich Process Approach for an Integrated Management System Change driven.
Steps for the Integration of Traditional Medicine in the National Health Care Delivery System 18 TH ICASA Special Session on Traditional Medicine 1 st.
Developing, Pilot Testing & Evaluating RiskMAP Interventions Annette Stemhagen, DrPH, FISPE Vice President UBC Epidemiology & Risk Management The FDA Regulatory.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Medical Necessity Criteria An Overview of Key Components Presented by BHM Healthcare Solutions.
PD233: Design of Biomedical Devices and Systems (Lecture 2) Dr. Manish Arora CPDM, IISc Course Website:
© 2016 Chapter 6 Data Management Health Information Management Technology: An Applied Approach.
Regulatory Updates Health Sciences Authority Singapore
Executive Director, Registrar Corp
GCP AND MEDICAL DEVICES
Overview of regulatory and compliance in software development for medical devices
Proposal for a Regulation on medical devices and Proposal for a Regulation on in vitro diagnostic medical devices Key Provisions and GIRP Assessment.
THE 13TH NATIONAL HIPAA SUMMIT HEALTH INFORMATION PRIVACY & SECURITY IN SHARED HEALTH RECORD SYSTEMS SEPTEMBER 26, 2006 Paul T. Smith, Esq. Partner,
MEDICAL DEVICES CONTROL SYSTEM IN INDONESIA
Opening an IND: Investigator Perspective
Regulatory Perspective of the Use of EHRs in RCTs
Risk Stratification for Care Management
Presentation transcript:

FDASIA Taxonomy Subgroup HIT Policy Committee FDASIA Workgroup On Site Meeting 30 May 2013

Subgroup Co-Chairs Patti Brennan Meghan Dierks

Charge 1 Charge, Anticipated Output of Subgroup 1

To identify the scope of Health IT that should be considered or included in deliberation by the full workgroup … as the full workgroup develops strategy and recommendations on an appropriate, risk-based regulatory framework for health IT that promotes innovation, protects patient safety, and avoids unnecessary and duplicative regulation. Taxonomy Subgroup Charge – Anticipated Output

To identify the scope of Health IT that should be considered or included in deliberation by the full workgroup Taxonomy subgroup scope not to be interpreted as being the final recommendation for what is to be regulation Taxonomy Subgroup Charge – Anticipated Output

Charge 2 Statutory Definitions 2

The term “health information” means any information, whether oral or recorded in any form or medium, that— (A) is created or received by a health care provider, health plan, public health authority, employer, life insurer, school or university, or health care clearinghouse; and (B) relates to the past, present, or future physical or mental health or condition of an individual, the provision of health care to an individual, or the past, present, or future payment for the provision of health care to an individual. Statutory Definitions Health Information [ SSA § 1171(4); 42 U.S.C. 1320d ]

“The term ‘health information technology’ means hardware, software, integrated technologies or related licenses, intellectual property, upgrades, or packaged solutions sold as services that are designed for or support the use by health care entities or patients for the electronic creation, maintenance, access, or exchange of health information.” Statutory Definitions Health Information Technology [ HITECH Act (2009) ]

” … an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory which is: — recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them, — intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or — intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes." Statutory Definitions Medical Device [ Federal Food, Drug and Cosmetic Act 21 CFR ]

Scope Options 3

Scope Options Considered EXISTING TECHNOLOGY FOCUS: Explicitly limit scope to existing, named types or categories of Health IT EXCLUSIONARY FOCUS: Explicitly exclude named types of Health IT as Not-in-Scope; assume all else is In-Scope PRESCIPTIVE/INCLUSIONARY FOCUS: Explicitly include named types of Health IT as In-Scope, assume all else is Out-of- Scope

Scope Options Considered STATUTORY DEFINITION FOCUS: Explicitly state the scope as any software useable by patients or providers to create, maintain, access, or exchange health information Explicitly exclude from scope products that meet definition of medical device, hence fall under existing regulatory framework

Scope Options Considered USER TYPE FOCUS: Create a scope based on user type FUNCTIONALITY/INTENDED USE FOCUS: Create a scope where scope driven by Health IT’s functionality and intended use RISK-HARM FOCUS: Create a scope based on potential for injury or harm with failures, malfunctions, foreseeable misuse

Organizing Principles 4

Platform agnostic — e.g., Scope is not defined by ‘Wireless’/wired Mobile/fixed Installed versus Software as a Service (SaaS) Avoid creating list of specific examples — Attempt to define generically — For product categories – focus on functions/intended use

Organizing Principles Part-Whole: — If ‘component’ or part is in-scope, the whole is in scope

Scope Dimensions Considered Product Categories ﹣ … User Type ﹣ … Phases of product lifecycle ﹣ … Developer/ ‘Manufacturer’ Type ﹣ … Distribution Model ﹣ … Conditions of use ﹣ …

Scoping 5

User Types Health Care Providers – institutional and individual Clinical Researchers using on human subjects Patients under care by a provider General public user/consumer under own use/health management In ScopePotentially Out of Scope

Product Lifecycle Design phase: use of risk-mitigating design controls, standards, requirements, documentation, labeling Implementation- Installation: Configuration mgmt, interfacing with other systems, interoperability as systems-of-systems In ScopePotentially Out of Scope

Product Lifecycle Design phase Implementation- Installation Maintenance: Routine updates/upgrades, performance tuning, defect and safety-related corrective, enhancements and Δ to base functionality In ScopePotentially Out of Scope

Product Lifecycle Design phase Implementation- Installation Maintenance Recall: Managing entire install base (vs. index customer), maintaining configuration log In ScopePotentially Out of Scope

Product Lifecycle Design phase Implementation- Installation Maintenance Recall End-of-Life Support: De-installation of out-dated or non-conforming product (vis-à-vis contemporary standards) In ScopePotentially Out of Scope

Product Lifecycle Design phase Implementation- Installation Maintenance Recall End-of-Life Support Cybersecurity: Control of PHI, assuring protection against malware-based risks In ScopePotentially Out of Scope

Product Lifecycle Design phase Implementation- Installation Maintenance Recall End-of-Life Support Cybersecurity Methods and modes of end-user training In ScopePotentially Out of Scope

Developer/ ‘Manufacturer’ Types Entity who develops/markets/licenses/d istributes products with commercial interest Healthcare provider* who develops products de novo for use on patients, even if no direct or indirect commercial interest Healthcare provider* who modifies functionality of previously licensed, ‘finished’ products In ScopePotentially Out of Scope *institutional or individual provider

Developer/ ‘Manufacturer’ Types Independent entity who develops/ advertises/distributes via public channel products intended for general public users, even if no commercial interest In ScopePotentially Out of Scope

Developer/ ‘Manufacturer’ Types Entity who develops/markets/licenses/distrib utes products with commercial interest Healthcare provider* who develops products de novo for use on patients, even if no direct or indirect commercial interest Healthcare provider* who modifies functionality of previously licensed, ‘finished’ products Independent entity who develops/ advertises/distributes via public channel products intended for general public users, even if no commercial interest Individuals who develop for personal private use Individual who develops/distributes via private channel to limited individuals without commercial interest Independent non- commercial developers who advertise/distribute via public channel products intended for general public users In ScopePotentially Out of Scope *institutional or individual provider

Distribution Model Marketed-licensed- distributed-sold in a restricted manner, with credentialing requirements Marketed-licensed- distributed-sold in a restricted manner, without credentialing requirements Made available for download via an unrestricted public channel, with or without credentialing requirements Available under a SaaS model In ScopePotentially Out of Scope

General Conditions of Use Intended use Foreseeable misuse Non-foreseeable, willful misuse Use clearly beyond labeled intended use In ScopePotentially Out of Scope

General Conditions of Use By prescription, recommendation or under direction of licensed/credentialed healthcare provider Independently by general public consumer/user For management of defined illness or chronic condition ? For health maintenance or fitness In ScopePotentially Out of Scope

Specific Product Types - Categories In ScopePotentially Out of Scope

Decision Tree Approach Functionality – Intended Use – Potential for Harm

Diagram Does product currently meet FDA (Act 21 CFR) definition of Medical Device (including MDDS) ? Does product currently meet FDA (Act 21 CFR) definition of Medical Device (including MDDS) ? NO YES Out-of-scope … defer to existing regulatory framework Potentially in-scope

Diagram 2 Does malfunction, foreseeable misuse have potential to cause patient injury, via: Delay or failure to present clinical data/ information at time of need Presentation of outdated information Patient-data mismatch ? YES NO Potentially in-scope Potentially out-of-scope

Diagram 3 Is the data/information that is managed by system the sole or 1 o source of data at point of care (i.e., no alternate sources of data /info that can be used for confirmation) ? YES NO Potentially in-scope Potentially out-of-scope

Diagram 4 Through design and intended use, is patient or provider reliant on data/information to initiate or modify prescribed intervention or tx ? YES NO Potentially in-scope Potentially out-of-scope

Diagram 5 Through design and intended use, is patient or provider reliant on alerting or function about a change in clinical status and/or a need to initiate or modify tx ? YES NO Potentially out-of-scope Potentially in-scope

Products Types - Categories Claims processing Health benefit eligibility Practice management / Scheduling / Inventory management Healthcare provider communication tools (e.g., , paging) Population management tools Software using historical claims data to predict future utilization/cost of care Cost effectiveness analytic software In ScopeOut of Scope

Products Types - Categories Diseases severity scoring algorithms Electronic guideline distribution Disease registries In ScopeOut of Scope

Products Types - Categories EHRs (installed, SaaS) Hospital Information Systems-of-systems Decision support algorithms Visualization tools for anatomic, tissue images, medical imaging and waveforms ? Health Information Exchanges Electronic/robotic patient care assistants Claims processing Health benefit eligibility Practice management / Scheduling / Inventory management Healthcare provider communication tools (e.g., , paging) Population management tools Software using historical claims data to predict future utilization/cost of care Cost effectiveness analytic software Diseases severity scoring algorithms Electronic guideline distribution Disease registries In ScopeOut of Scope

Strive to: — develop a framework that is able to meet future undefined needs — avoid a discrete, static and specific defined list of named products Favor the decision tree approach that emphasizes functionality as a primary scoping criterion Words of Caution

Questions and Discussion